Glenn Sblendorio, MBA, is Chief Executive Officer of Iveric Bio. He joined the Company in 2016 as Executive Vice President, Chief Operating Officer, and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. He ceased being CFO in April 2017. Mr. Sblendorio served as a member of the board of directors of Iveric Bio from 2013 to 2016 and rejoined the board in May 2017. Prior to joining Iveric Bio, he served as President and Chief Financial Officer and member of the board of directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the board of directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his BA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.

Dr. Dugel was previously Managing Partner, Retinal Consultants of Arizona and the Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California; and Founding Member, Spectra Eye Institute in Sun City, Arizona.

Dr. Dugel has authored more than 200 papers, 35 book chapters, and has been invited to give prestigious named lectures at marquis medical meetings and to serve as a visiting professor at universities worldwide, including in Japan, India, Nepal, China, Malaysia, Egypt, the United Kingdom, France, Germany, Austria, Italy, Poland, Denmark, Norway, Czechoslovakia, Canada, and Australia. He is on the editorial board of several major medical journals. Dr. Dugel is internationally recognized as a major clinical researcher and has been a principal investigator in over 100 multicenter clinical trials. His research and educational contributions earned him the prestigious Honor Award, Senior Honor Award and Lifetime Achievement Award from the American Academy of Ophthalmology (AAO). He has been elected and previously served as the Retina Subspecialty Day Board Chairman for the American Academy of Ophthalmology Annual Meeting, as a member of the board of directors of the largest retina society in the United States, the American Society of Retina Specialists (ASRS), and the largest retina society in Europe, EURETINA. Additionally, he has been elected to the Retina Society, Macula Society, and the Retina Hall of Fame.

Dr Dugel has served as the Chair of the Scientific Advisory Board for major companies, including Novartis, Roche, Genentech, Allergan (Abbvie), Oxurion (Thrombogenics), Oculis, and Alcon. He has consulted for over 50 companies and has served on the Aerpio Therapeutics board of directors.

Dr. Dugel has been a member of the board of directors and Chair of Orbis International’s Medical Advisory Board and Medical Strategic Committee. Orbis International is a non-profit organization focused on ophthalmology training and education in the developing world. With Orbis, Dr. Dugel travels to developing countries to teach surgical techniques to local ophthalmologists and provide free surgery. In Arizona, Dr. Dugel founded an aviation company allowing him to travel to the Navajo, Hopi and Pima Indian Reservations to treat Native American patients suffering from preventable blindness.

Dr. Dugel was born in Kathmandu, Nepal, grew up in Vienna, Austria and attended Harrow School in London, England. He graduated Summa cum Laude from Columbia University in New York City and was elected to the Phi Beta Kappa Society. He was also captain of the Columbia Squash team. He then attended UCLA School of Medicine, then residency in ophthalmology at the USC Eye Institute, Keck School of Medicine. Thereafter, he completed his medical retina fellowship at the Bascom Palmer Eye Institute and his surgical retina fellowship at the USC Eye Institute, where he received both the Heed Foundation Fellowship award and Ronald G. Michels Foundation Fellowship award.

Tony Gibney is Executive Vice President and Chief Business and Strategy Officer of Iveric Bio. Mr. Gibney is an experienced biotechnology executive and former investment banker with over 25 years of experience dedicated to advising biotechnology companies. Before joining Iveric Bio, Mr. Gibney served as Chief Financial Officer and Chief Business Officer at Fog Pharmaceuticals overseeing the business development, strategy and finance functions of the company. Previously, Mr. Gibney was Executive Vice President and Chief Business Officer at Achillion Pharmaceuticals, where he led the successful sale of Achillion to Alexion Pharmaceuticals in 2020. Before Achillion, Mr. Gibney was a Managing Director and Co-Head of the Biotechnology Investment Banking Team at Leerink Partners LLC, and Managing Director of Merrill Lynch’s Healthcare Group. Mr. Gibney has executed over 150 financings and merger and acquisition advisory transactions for U.S. and European clients. He earned a B.A. in Economics and a B.A. in History from Yale University.

Todd D.C. Anderman is Chief Legal Officer & Corporate Secretary of Iveric Bio. Mr. Anderman joined the Company in 2015 after representing the Company since 2012 while practicing corporate law at Wilmer Cutler Pickering Hale and Dorr LLP. While at WilmerHale, Mr. Anderman’s practice focused on representing life sciences and technology companies. Mr. Anderman began his career as a corporate attorney at Cravath, Swaine & Moore LLP. Mr. Anderman has extensive experience advising on merger, acquisition, divestiture, licensing, and financing transactions. Mr. Anderman received his BA in government and philosophy from the College of Arts & Sciences at Cornell University and his JD from the University of Pennsylvania Law School.

David Carroll, M.B.A, is the Chief Financial Officer of Iveric Bio. Mr. Carroll joined the Company in 2016 and has more than 25 years of experience in the life sciences industry. Prior to joining the Company, Mr. Carroll spent eight years at The Medicines Company in several senior financial leadership roles, including Vice President, Controller, and most recently, Senior Vice President, Chief Accounting Officer. Earlier in his career, Mr. Carroll served in various financial management positions of increasing responsibility for Genentech, Novartis, and Bristol-Myers Squibb. Mr. Carroll is a certified public accountant and received a BA from Ursinus College magna cum laude and an MBA from Rutgers University.

Dr. Xiao-Ping Dai is Chief Technical Officer of Iveric Bio, responsible for manufacturing and CMC development of the product pipeline. She joined the company in 2019.

Dr. Dai has more than 20 years of experience in the biopharmaceutical industry, specialized in product and process development and manufacturing. She has successfully developed processes and managed overall CMC development for more than 30 different biological products including monoclonal antibodies, fusion proteins, pegylated proteins, ADCs, multi-specific antibodies and vaccines, from preclinical development through commercialization, including Opdivo and Yervoy. Dr. Dai has a proven track record of internal and external development, with CDMOs/CMOs, managing multiple partnerships and collaborations, technology transfers, scale-ups, process performance qualifications (PPQ) and regulatory filings.

Prior to joining Iveric Bio, Dr. Dai was Chief Technologist and VP of Process and Technology Development at WuXi Advanced Therapy, a CDMO where she built and led an organization engaged in process and technology platform development, serving cell and gene therapy clients. Prior to joining WuXi, Dr. Dai was Sr. Director of Biologics Development and Manufacturing at Celgene Corporation, where she built and led a strong technical team and successfully delivered on multiple internal and external programs. Prior to Celgene, Dr. Dai had over 13 years of effective functional and cross-functional leadership and technical experience in Biologics Development at BMS, Medarex and Regeneron Pharmaceuticals, and before that at NJIT, where she received her PhD in Chemical Engineering.

Dhaval Desai, PharmD, is Senior Vice-President and Chief Development Officer at Iveric Bio. Dr. Desai joined Iveric Bio as Chief of Staff in 2020 after serving as Vice President and Medical Unit Head of US Ophthalmics at Novartis. During his time at Novartis, Dr. Desai was responsible for the establishment of a US Ophthalmics unit and developing a comprehensive franchise strategy. Prior to Novartis, Dr. Desai held multiple leadership roles in ophthalmology-focused companies including Aerpio Pharmaceuticals, where he served as Vice President of Medical Affairs and Chief Strategic Officer, and ThromboGenics, where he served as Global Director, Medical Affairs. Dr. Desai received his PharmD and completed his post-doctoral fellowship at Rutgers University.

Kathy Galante is Senior Vice President, Investor Relations at Iveric Bio. Ms. Galante joined the Company in 2013 and has more than 25 years of investor relations experience in the biotechnology industry. Prior to Iveric Bio, Ms. Galante was a Senior Vice President at Burns McClellen, where she was responsible for creating and implementing investor relations programs for both publicly traded and privately held life science companies. Before that, Ms. Galante spent more than two decades at then Nasdaq-listed OSI Pharmaceuticals, where she was instrumental in the development of the company’s investor relations and corporate communications strategy, as well as managing public relations around the launch of Tarceva^®. During her tenure at OSI Pharmaceuticals, Ms. Galante was a key member of the management team that transformed a small, $200 million research-based biotechnology company into a profitable, $4 billion biopharmaceutical organization with discovery, development, and commercialization capabilities.

Evelyn Harrison, MBA, is the Senior Vice President & Chief Clinical Operations Officer of Iveric Bio. She brings more than 33 years of management and clinical research experience. Prior to joining Iveric Bio, Ms. Harrison was with Eyetech Pharmaceuticals, Inc., where she held the management positions of Vice President and Senior Vice President of Clinical Research and Development. While at Eyetech, Ms. Harrison played a key role in the development and approval of Macugen^® (pegaptanib sodium) for the treatment of wet age-related macular degeneration.

Ms. Harrison’s professional career began in clinical research at a major New York City teaching hospital. She then moved to Hoffmann-La Roche Inc., where she was Director of Clinical Operations, responsible for the development and implementation of strategic programs for Roche’s oncology franchise.

Ms. Harrison has worked on all phases of global clinical trials and has extensive experience in multiple therapeutic areas such as bone marrow transplantation, organ transplantation, oncology and virology.

Ms. Harrison holds a BA degree in biology from Hofstra University and an MBA from Manhattan College.

Dr. Snehal Shah is Senior Vice President, Chief Regulatory & Product Strategy Officer at Iveric Bio. Dr. Shah brings over 18 years of global experience in Regulatory Affairs, Pharmacovigilance and Product Strategy, gained at leading pharmaceutical companies including Hoffmann La-Roche/ Genentech, Noven Pharmaceuticals (Member of the Hisamitsu Group) and Kyowa Kirin.

Dr. Shah has led both biologics and small molecule development programs focusing on rare orphan diseases, oncology, neurology, virology, transplantation, inflammation, endocrinology, and women’s health; at all product lifecycle phases through commercialization. Most notably Dr. Shah has provided strategic leadership to successfully bring over a dozen market applications from filing through approval, allowing new treatment options for patients. This includes first in class treatments for rheumatoid arthritis, vasomotor symptoms associated with menopause, cutaneous T-cell lymphoma, and Parkinson’s disease.

Dr. Shah holds a B.S. in pharmacy from Rutgers University and a Doctorate of Pharmacy from the University of Kansas. He also completed the American Course of Drug Development and Regulatory Sciences Certification program at the University of California, San Francisco.

Amy Sheehan is the Senior Vice President & Chief Human Resources Officer at Iveric Bio. Ms. Sheehan joined the Company in 2014 and brings over 20 years of human resources experience in the biotechnology and manufacturing industries. Prior to joining Iveric Bio Ms. Sheehan led Human Resources for the Electronic Systems Division of Parker Hannifin, a publicly traded Fortune 250 global company. Earlier in Ms. Sheehan’s career she held leadership positions of increasing responsibility in human resources at OSI Pharmaceuticals, a publicly traded biotechnology company. Throughout Ms. Sheehan’s career she oversaw Human Resources teams and led successful HR strategies in talent acquisition, culture, total rewards, leadership development, and training. She holds a MS in human resources management and a BA in psychology from Hofstra University.

Chris Simms is Senior Vice President and Chief Commercial Officer of Iveric Bio. Mr. Simms is an accomplished healthcare leader with more than 20 years of diverse commercial leadership experience at Johnson & Johnson, Genentech, and Novartis, including focused experience in retina, ophthalmology, and optometry. Most recently, he was the Vice President and Head of the Novartis US Ophthalmics business unit which includes the brands BEOVU^® and Xiidra^®. He joined Novartis in 2017 to build the commercial launch strategy for BEOVU^® after leading commercial efforts on Lucentis^® at Genentech. Prior to Genentech, he spent 16 years at Johnson & Johnson working with leading brands across their vision care, diabetes and consumer goods businesses in Canada, Japan, and the US. Mr. Simms has a Bachelor of Commerce from Memorial University of Newfoundland and an MBA from York University, Toronto, Canada.

Keith Westby is Senior Vice President and Chief Operating Officer of Iveric Bio. Mr. Westby joined the Company in 2007 and has over 20 years of experience in program and strategic alliance management and manufacturing operations in biotechnology companies. Mr. Westby was most recently Senior Vice President, Development Operations. Prior to joining the Company, Mr. Westby worked at Pharmasset, Inc., as Director, Project and Alliance Management. He also served in positions of increasing responsibility at Eyetech Pharmaceuticals, including Director, Alliance & Project Management, leading multifunctional project teams in the New Drug Application filing and marketing approval of Macugen. Previously, Mr. Westby worked at Tunnell Consulting, where he was a Senior Consultant in the firm’s Life Sciences practice focused on manufacturing operations and process improvement. Mr. Westby holds a BS in applied physics from the State University of New York, College at Geneseo, a MS in engineering management from Drexel University, and a MBA degree from Columbia Business School.

Adrienne Graves, Ph.D. – Dr. Adrienne Graves is a visual scientist by training and a global industry leader in ophthalmology. As the former CEO of Santen Inc., she successfully established a strong global presence, brought multiple ophthalmic products through development to approval and commercialization, and led global teams through successful acquisitions and partnerships. At Santen, Dr. Graves served as Sr. VP of Worldwide Clinical Development (US, Europe, and Japan) for 7 years and CEO for 8 years. Prior to Santen, she spent 9 years at Alcon, joining as Sr. Scientist to establish Alcon’s first Retinal Electrophysiology Laboratory. She progressed through roles of increasing responsibility in R&D, including directing clinical development in multiple therapeutic areas and serving as Director of International Ophthalmology. Dr. Graves currently serves as an Independent Director on the boards of Iveric Bio, Qlaris Bio, Nicox S.A., Surface Ophthalmics, Oxurion, TherOptix, and Greenbrook TMS. She previously held board positions at Encore Vision (2011 – 2017; acquired by Novartis), Envisia Therapeutics (2014 – 2017; assets acquired by Aerie Pharmaceuticals), TearLab Corporation (2005 – 2018), Aerpio Therapeutics (2012 – 2017), and Akorn (2012 – 2020). Dr. Graves also serves as Director on the following Foundation Boards: American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, Foundation Fighting Blindness (FFB), and the RD (Retinal Degeneration) Fund. Dr. Graves co-founded Glaucoma 360 and OWL (Ophthalmic World Leaders, formerly Ophthalmic Women Leaders). Her recent honors include the Visionary Award from Foundation Fighting Blindness, the Catalyst Award from Glaucoma Research Foundation, the Visionary Award from OWL, the Bernice Brown Memorial Lecture and award from Women in Ophthalmology, and The Ophthalmologist 2021 Power List. Dr. Graves received an AB with Honors in Psychology from Brown University, a Ph.D. in Psychobiology/Neuroscience from the University of Michigan, and she completed a Postdoctoral Fellowship in Visual Neuroscience at the University of Paris. She is a Visionary Innovation Mentor at the Ophthalmic Innovation Program at Stanford University.

Mark S. Blumenkranz, MD, MMS, is HJ Smead Professor Emeritus in the Department of Ophthalmology at Stanford University, where he is the co-director of the Ophthalmic Innovation Program. Dr. Blumenkranz is a co-founder and the Chief Executive Officer and Chairman of Kedalion Therapeutics and currently serves as a director of Verana Health, BVI Visitec, Combangio Corporation, and One Medical (ONEM:NASDAQ). Dr. Blumenkranz is also a Managing Director of Lagunita Biosciences, an early stage biotechnology and medical investment company and incubator.

He was a co-founder and served on the boards of Optimedica Corporation (acquired by AMO), Peak Surgical (acquired by Medtronics), Adverum Biotechnologies (ADVM:NASDAQ), and Oculeve (acquired by Allergan). He also co-founded Verana Health (formerly Digisight Technologies) and Combangio Corporation, both clinical-stage privately held venture-backed companies in Silicon Valley, and continues to serve on their boards. In the past he served as an independent Director at Oculex Pharmaceuticals (acquired by Allergan), and Presbia.

Dr. Blumenkranz has a longstanding interest and expertise in university corporate technology transfer and early stage biomedical company formation and is the author of more than 160 peer-reviewed articles and more than 18 issued patents including the Pascal and Catalys lasers. He is a past president of the American University Professors of Ophthalmology, the Retina Society, the Macula Society, and a Fellow Emeritus of the Corporation of Brown University, where he served as the Chair of the Medical School Committee.

Dr. Blumenkranz received his undergraduate, graduate, and medical degrees at Brown; his ophthalmic residency training at Stanford; and a fellowship in vitreo-retinal diseases at the Bascom Palmer Eye Institute. He served as the Chair of the Ophthalmology Department at Stanford from 1997 until 2015 and played a leading role in the planning, fundraising, and construction of the Byers Eye Institute there.

Mr. Bolte has served as a member of our board of directors since August 2007. Since February 2017, Mr. Bolte has served as president and chief executive officer of Inozyme Pharma Inc., a publicly traded biotechnology company. Mr. Bolte previously served as a managing member of Healthcare Advisors GmbH, a private healthcare advisory company. From February 2017 to September 2019, Mr. Bolte served as a venture partner to HBM Partners AG, a provider of investment advisory services in the life sciences industry, and where he previously served as an investment advisor from March 2003 through January 2017. From March 2001 to February 2003, Mr. Bolte was an investment manager of NMT New Medical Technologies AG, a Swiss venture capital company focused on life sciences. Prior to joining NMT New Medical Technologies AG, Mr. Bolte served as a scientist at Serono SA, a biotechnology company. Mr. Bolte currently serves on the board of directors of Nabriva Therapeutics AG and previously served on the board of directors of PTC Therapeutics, Inc., both of which are publicly traded biotechnology companies. Mr. Bolte received a degree in biochemistry from the Swiss Federal Institute of Technology, Zurich, Switzerland and an MBA from the University of St. Gallen, Switzerland.

Dr. Dugel was previously Managing Partner, Retinal Consultants of Arizona and the Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California; and Founding Member, Spectra Eye Institute in Sun City, Arizona.

Dr. Dugel has authored more than 200 papers, 35 book chapters, and has been invited to give prestigious named lectures at marquis medical meetings and to serve as a visiting professor at universities worldwide, including in Japan, India, Nepal, China, Malaysia, Egypt, the United Kingdom, France, Germany, Austria, Italy, Poland, Denmark, Norway, Czechoslovakia, Canada, and Australia. He is on the editorial board of several major medical journals. Dr. Dugel is internationally recognized as a major clinical researcher and has been a principal investigator in over 100 multicenter clinical trials. His research and educational contributions earned him the prestigious Honor Award, Senior Honor Award and Lifetime Achievement Award from the American Academy of Ophthalmology (AAO). He has been elected and previously served as the Retina Subspecialty Day Board Chairman for the American Academy of Ophthalmology Annual Meeting, as a member of the board of directors of the largest retina society in the United States, the American Society of Retina Specialists (ASRS), and the largest retina society in Europe, EURETINA. Additionally, he has been elected to the Retina Society, Macula Society, and the Retina Hall of Fame.

Dr Dugel has served as the Chair of the Scientific Advisory Board for major companies, including Novartis, Roche, Genentech, Allergan (Abbvie), Oxurion (Thrombogenics), Oculis, and Alcon. He has consulted for over 50 companies and has served on the Aerpio Therapeutics board of directors.

Dr. Dugel has been a member of the board of directors and Chair of Orbis International’s Medical Advisory Board and Medical Strategic Committee. Orbis International is a non-profit organization focused on ophthalmology training and education in the developing world. With Orbis, Dr. Dugel travels to developing countries to teach surgical techniques to local ophthalmologists and provide free surgery. In Arizona, Dr. Dugel founded an aviation company allowing him to travel to the Navajo, Hopi and Pima Indian Reservations to treat Native American patients suffering from preventable blindness.

Dr. Dugel was born in Kathmandu, Nepal, grew up in Vienna, Austria and attended Harrow School in London, England. He graduated Summa cum Laude from Columbia University in New York City and was elected to the Phi Beta Kappa Society. He was also captain of the Columbia Squash team. He then attended UCLA School of Medicine, then residency in ophthalmology at the USC Eye Institute, Keck School of Medicine. Thereafter, he completed his medical retina fellowship at the Bascom Palmer Eye Institute and his surgical retina fellowship at the USC Eye Institute, where he received both the Heed Foundation Fellowship award and Ronald G. Michels Foundation Fellowship award.

Jane Pritchett Henderson has more than 32 years of experience in the life sciences industry and health care investment banking. She currently serves as Chief Financial Officer at Apogee Therapeutics, a company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders. Previously Ms. Henderson served as Chief Financial Officer at Adagio Therapeutics, a company developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV and additional pre-emergent coronaviruses. Prior to Adagio, Ms. Henderson served as Chief Financial Officer at Turnstone Biologics, a clinical-stage immuno-oncology company. Prior to Turnstone, Ms. Henderson served as CFO and Senior Vice President of Corporate Development at Voyager Therapeutics, a publicly-traded, clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Prior to Voyager, Ms. Henderson served as Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., having joined the privately held biopharmaceutical company in 2013 and leading the sale of Kolltan to Celldex Pharmaceuticals, Inc. in late 2016. Previously, Ms. Henderson served as Vice President, Business Development of ISTA Pharmaceuticals, Inc., until ISTA Pharmaceuticals was acquired by Bausch + Lomb. Prior to ISTA Pharmaceuticals, Ms. Henderson served as Chief Financial Officer and Head of Business Development at Axerion Pharmaceuticals, Inc., and as Chief Financial Officer and Chief Business Officer of Panacos Pharmaceuticals, Inc. In addition to her industry experience, Ms. Henderson’s extensive healthcare investment banking experience includes the execution of more than 95 mergers and acquisitions, advisory and financing deals as managing director and other senior roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson holds a B.S. in psychology from Duke University and currently serves on the board of directors of Akero Therapeutics, a publicly traded, clinical-stage company focused on NASH.

Christine Ann Miller has served as President and Chief Executive Officer and as a member of the board of Melinta Therapeutics since August 2020. Ms. Miller is a global pharmaceutical veteran with more than 20 years of experience in life sciences. Most recently, Ms. Miller led the global and U.S. product portfolio for Sandoz, a $10 billion division of Novartis, where she was accountable for transitioning the portfolio toward- rapid-growth and higher-margin segments, such as complex generics and value-added medicines, while continuing to build the branded generics business.

Among her various achievements, Ms. Miller directed more than 50 product launches that generated over $300 million of new annual revenue, closed numerous business development acquisitions, and built a robust five-year development and acquisition product pipeline. Before Sandoz, Ms. Miller spent over a decade at Actavis (now Allergan) and its predecessor Watson Pharmaceuticals where she led the preparation of numerous product launches and held leadership roles in both R&D operations and supply chain management.

Ms. Miller started her career at Merck as a chemical engineer and procurement analyst and earned an MBA and a Master’s in Technology Management at Stevens Institute of Technology and a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute.
Ms. Miller’s leadership focus combines her passion for building and leading high performing teams with goal-driven operational rigor. She articulates a clear mission, vision and strategy that engages people to cohesively work towards creative problem solving and innovative solutions.
She serves as an Advisory Board Member for the Healthcare Businesswomen’s Association and is a frequent panelist and speaker at industry events.

Calvin W. Roberts, MD is a renowned specialist in cataract and refractive surgery. Dr. Roberts is credited with developing surgical therapies, over-the-counter products for vision care, prescription ocular therapeutics, and innovative treatment regimens. Dr. Roberts is the President and CEO of Lighthouse Guild, the leading provider of services to those with vision loss. Formerly, Dr. Roberts served as Senior Vice President and the Chief Medical Officer, Eye Care at Bausch Health Companies. Since 1982, Dr. Roberts has been a Clinical Professor of Ophthalmology at Weill Medical College of Cornell University, and a founding member of the board of directors of Alimera Sciences. Dr. Roberts previously served as a consultant to Allergan, Inc., Johnson & Johnson, and Novartis. Dr. Roberts holds patents on the wide-field specular microscope, used for corneal endothelial studies, and was a pioneer in the use of ophthalmic non-steroidals.

Dr. Roberts received an AB from Princeton University and his MD from the College of Physicians and Surgeons of Columbia University. Dr. Roberts completed his internship and ophthalmology residency at Columbia Presbyterian Hospital. Dr. Roberts also completed cornea fellowships at Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute in Boston. Dr. Roberts currently serves as an Independent Director on multiple corporate boards.

Glenn Sblendorio, MBA, is Chief Executive Officer of Iveric Bio. He joined the Company in 2016 as Executive Vice President, Chief Operating Officer, and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. He ceased being CFO in April 2017. Mr. Sblendorio served as a member of the board of directors of Iveric Bio from 2013 to 2016 and rejoined the board in May 2017. Prior to joining Iveric Bio, he served as President and Chief Financial Officer and member of the board of directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the board of directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his BA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.